AstraZeneca stock holds as 2025 revenue and profit stay in focus

AstraZeneca stock is framed by its 2025 results, with revenue at $54.1 billion and core operating profit at $13.1 billion. The shares also come with a current market value anchor and a recent reporting context.

AstraZeneca stock is framed by 2025 results that showed total revenue of $54.1 billion, up 19% at constant exchange rates, while core operating profit reached $13.1 billion for the year. AstraZeneca plc (ISIN US6549022043) remains a large-cap health care name with a reporting base that gives investors a clear earnings reference point.

Revenue at $54.1 billion

The 2025 top line stood at $54.1 billion, supported by a 19% constant-currency increase and a 21% rise in reported revenue. That gap matters because it shows how exchange rates influenced the final dollar figure while the underlying business still expanded at a double-digit pace.

Core operating profit of $13.1 billion in 2025 gives a second anchor, and the company said core EPS reached $9.49 for the year. The comparison is straightforward: revenue grew faster than many mature pharma peers, while profit kept pace enough to preserve a high-margin earnings profile.

Profit and cash flow

AstraZeneca reported core EPS of $9.49 in 2025, which provides a direct earnings bridge for valuation work. The company also said operating income on a core basis reached $13.1 billion, a number that helps frame the scale of the business beyond headline revenue.

Free cash flow came in at $6.9 billion in 2025, giving the group room to support development spending and shareholder returns. In the same annual materials, management highlighted continued investment across oncology, biopharmaceuticals, and rare disease franchises, which keeps the revenue mix relevant for the next reporting cycle.

Market value anchor

For the stock itself, the latest market cap anchor available in the evidence set is $222.9 billion as of 2025, which keeps AstraZeneca in the global mega-cap bracket. That scale matters because it can soften the impact of one product cycle and makes the next earnings update more important than day-to-day noise.

AstraZeneca stock therefore trades on a mixture of durable earnings power and a large market capitalization base, with 2025 revenue of $54.1 billion, core operating profit of $13.1 billion, and core EPS of $9.49 offering the main numbers to watch.

Tagrisso still matters

Tagrisso remains one of the company’s best-known oncology products, and the franchise continues to matter because AstraZeneca’s annual results are still anchored by large specialist medicines rather than one-off events. The product mix across oncology and newer launch categories is the key reason the 2025 numbers deserve attention in any fresh stock read-through.

For investors, the real question is not the brand name itself but whether the company can keep translating the 2025 revenue base into another year of profit and cash generation. That is the part of the story that links the product portfolio to the $54.1 billion revenue figure and the $6.9 billion free cash flow result.

Closing price context

AstraZeneca stock is tied to the LSE and Nasdaq ADR structure, but the clearest dated market-value evidence in this call is the $222.9 billion market cap as of 2025. Combined with 2025 revenue of $54.1 billion and core EPS of $9.49, the stock has enough scale and reporting depth to stay tightly linked to the next results release.

AstraZeneca snapshot

• Company: AstraZeneca plc
• ISIN: US6549022043
• Ticker: NYSE: AZN
• Trading venue: Nasdaq
• Market capitalization: $222.9 billion (as of 2025)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: FTSE 100